Guyasuta Investment Advisors Inc. lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 2.4% during the 2nd quarter, Holdings Channel.com reports. The fund owned 897,212 shares of the biopharmaceutical company’s stock after buying an additional 21,219 shares during the period. Pfizer accounts for 2.5% of Guyasuta Investment Advisors Inc.’s investment portfolio, making the stock its 13th biggest holding. Guyasuta Investment Advisors Inc.’s holdings in Pfizer were worth $35,135,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also modified their holdings of the company. Usca Ria LLC grew its stake in shares of Pfizer by 11.6% in the 2nd quarter. Usca Ria LLC now owns 504,526 shares of the biopharmaceutical company’s stock valued at $19,757,000 after purchasing an additional 52,362 shares during the last quarter. Cito Capital Group LLC lifted its holdings in shares of Pfizer by 59.6% in the 1st quarter. Cito Capital Group LLC now owns 38,831 shares of the biopharmaceutical company’s stock valued at $1,407,000 after buying an additional 14,500 shares during the period. Advisor Group Holdings Inc. lifted its holdings in shares of Pfizer by 4.4% in the 2nd quarter. Advisor Group Holdings Inc. now owns 2,090,666 shares of the biopharmaceutical company’s stock valued at $81,925,000 after buying an additional 88,276 shares during the period. Guggenheim Capital LLC lifted its holdings in shares of Pfizer by 2.8% in the 1st quarter. Guggenheim Capital LLC now owns 1,461,508 shares of the biopharmaceutical company’s stock valued at $52,950,000 after buying an additional 40,497 shares during the period. Finally, Carolina Wealth Advisors LLC lifted its holdings in shares of Pfizer by 7.1% in the 2nd quarter. Carolina Wealth Advisors LLC now owns 112,745 shares of the biopharmaceutical company’s stock valued at $4,415,000 after buying an additional 7,456 shares during the period. 64.93% of the stock is currently owned by institutional investors and hedge funds.
In other Pfizer news, SVP Jennifer B. Damico sold 2,500 shares of the business’s stock in a transaction dated Friday, July 30th. The stock was sold at an average price of $42.86, for a total transaction of $107,150.00. Following the completion of the sale, the senior vice president now owns 11,430 shares of the company’s stock, valued at $489,889.80. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Jennifer B. Damico sold 1,661 shares of the business’s stock in a transaction dated Friday, August 13th. The shares were sold at an average price of $48.30, for a total value of $80,226.30. The disclosure for this sale can be found here. 0.05% of the stock is owned by insiders.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Wednesday, July 28th. The biopharmaceutical company reported $1.07 EPS for the quarter, beating the Zacks’ consensus estimate of $0.97 by $0.10. The business had revenue of $18.98 billion during the quarter, compared to the consensus estimate of $17.54 billion. Pfizer had a return on equity of 26.49% and a net margin of 23.06%. During the same quarter in the previous year, the business earned $0.78 earnings per share. On average, sell-side analysts predict that Pfizer Inc. will post 4.12 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 6th. Stockholders of record on Friday, November 5th will be given a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 3.55%. The ex-dividend date is Thursday, November 4th. Pfizer’s dividend payout ratio is currently 70.27%.
PFE has been the subject of several research reports. Mizuho lifted their price objective on Pfizer from $42.00 to $43.00 and gave the stock a “neutral” rating in a report on Friday, July 30th. Royal Bank of Canada set a $44.00 price objective on Pfizer in a report on Thursday, July 29th. The Goldman Sachs Group set a $48.00 price objective on Pfizer in a report on Thursday, July 29th. JPMorgan Chase & Co. lifted their price objective on Pfizer from $40.00 to $42.00 and gave the stock a “neutral” rating in a report on Monday, September 13th. Finally, Truist initiated coverage on Pfizer in a report on Tuesday, July 27th. They set a “buy” rating and a $43.00 price objective for the company. Eleven equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $42.85.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
Read More: QQQ ETF
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.